Serum levels of microRNAs in patients with heart failure

Diagnosis and risk stratification of patients with heart failure remain a challenge. The small non‐coding RNAs known as microRNAs regulate gene expression and seem to play an important role in the pathogenesis of heart failure. In the current study, we aim to characterize the levels of microRNAs in the sera of chronic systolic heart failure patients vs. controls and assess the possible correlation between elevation in the levels of specific microRNAs and clinical prognostic parameters in heart failure patients.

[1]  S. Colan,et al.  Association of Left Ventricular Dilation at Listing for Heart Transplant With Postlisting and Early Posttransplant Mortality in Children With Dilated Cardiomyopathy , 2009, Circulation. Heart failure.

[2]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[3]  Steffen Scheer,et al.  Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure , 2011, European journal of heart failure.

[4]  D. Erlinge,et al.  Cardiospecific microRNA Plasma Levels Correlate with Troponin and Cardiac Function in Patients with ST Elevation Myocardial Infarction, Are Selectively Dependent on Renal Elimination, and Can Be Detected in Urine Samples , 2011, Cardiology.

[5]  P. P. Rickham.  HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI. , 1964, British medical journal.

[6]  Jun Li,et al.  An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. , 2010, Gynecologic oncology.

[7]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[8]  Thomas Thum,et al.  MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure , 2007, Circulation.

[9]  Frank Speleman,et al.  A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.

[10]  Rickham Pp.  Human Experimentation: Code of Ethics of the World Medical Association (Declaration of Helsinki). , 1964, Canadian Medical Association journal.

[11]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[12]  B. Gandevia,et al.  DECLARATION OF HELSINKI. , 1964, The Medical journal of Australia.

[13]  G. Hirokawa,et al.  Plasma miR-208 as a biomarker of myocardial injury. , 2009, Clinical chemistry.

[14]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[15]  Maureen A. Sartor,et al.  MicroRNA-320 Is Involved in the Regulation of Cardiac Ischemia/Reperfusion Injury by Targeting Heat-Shock Protein 20 , 2009, Circulation.

[16]  Martin W. McBride,et al.  Gene expression profiling in whole blood of patients with coronary artery disease , 2010, Clinical science.

[17]  A. LaCroix,et al.  Electrocardiographic Predictors of Incident Congestive Heart Failure and All-Cause Mortality in Postmenopausal Women: The Women’s Health Initiative , 2006, Circulation.

[18]  W. Zacharias,et al.  Exosome isolation for proteomic analyses and RNA profiling. , 2011, Methods in molecular biology.

[19]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[20]  Derek J Van Booven,et al.  Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support , 2009, Circulation.

[21]  D. Mann,et al.  Role of MicroRNAs in Cardiac Remodeling and Heart Failure , 2011, Cardiovascular Drugs and Therapy.

[22]  T. Shioi,et al.  MicroRNA, emerging role as a biomarker of heart failure. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[23]  R. Duisters,et al.  MIRNA-133 AND MIRNA-30 REGULATE CONNECTIVE TISSUE GROWTH FACTOR: IMPLICATIONS FOR A ROLE OF MIRNAS IN MYOCARDIAL MATRIX REMODELING , 2013 .

[24]  Perry D Moerland,et al.  MiR423-5p As a Circulating Biomarker for Heart Failure , 2010, Circulation research.

[25]  H. Uno,et al.  Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. , 2008, European heart journal.

[26]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[27]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[28]  B. Lewis,et al.  Genotype-phenotype associations between chymase and angiotensin—converting enzyme gene polymorphisms in chronic systolic heart failure patients , 2008, Genetics in Medicine.

[29]  M. Michael,et al.  Review: The role of microRNAs in kidney disease , 2010, Nephrology.

[30]  H. Nonogi,et al.  Assessment of plasma miRNAs in congestive heart failure. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[31]  Li-Ling Wu,et al.  Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts. , 2011, Cardiovascular research.

[32]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[33]  Stefanie Dimmeler,et al.  MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice , 2009, Science.

[34]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[35]  Arunmozhiarasi Armugam,et al.  MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus , 2011, PloS one.

[36]  R. Aharonov,et al.  Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin , 2010, Modern Pathology.